// App-Quantinova.ai

BIOM-15 : SERUM AMYLOID-β42 AS A NONINVASIVE BIOMARKER FOR PROGNOSIS AND HISTOLOGIC FEATURES OF GLIOMA

Researchers

Presenter

  • Kihwan Hwang

Principal Investigators

  • Minhee Noh

  • Jay Park

  • So Young Ji

  • Jung Ho Han

  • Kwang Sung Ahn

  • Chae-yong Kim

Medical Centers

  • PDXen Co, Daejeon, Republic of Korea

  • The University of Edinburgh, Edinburgh, UK

  • Seoul National University College of Medicine, Seoul, Republic of Korea

  • Seoul National University Bundang Hospital, Seongnamsi, Republic of Korea

Locations

  • Republic of South Korea

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gliomas

Biomarkers

  • Amyloid beta 42

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved